Applications of new laboratory marker assays in neurological diagnoses - a pilot study.
225 consecutive patients with different neurological diseases and 101 individuals as the control were examined between 2002-2004. Cystatin C, arginase-I, tau-protein and beta-amyloid were measured. Individuals with CNS inflammation had significantly lower Cystatin-C index (CSF/serum) values. There was no diagnostic significance of the Arginase-I assay in CSF was verified. The CSF tau-protein/beta-amyloid index was shown to be a sufficient efficacy for neurodegenerative disease diagnosis.
Stejskal
David
D
Department of Laboratory Medicine, Sternberk Hospital, Czech Republic. david.stejskal@quick.cz
Vavrousková
Jitka
J
Mares
Jan
J
Urbánek
Karel
K
D016229:Amyloid beta-Peptides / Q000134:cerebrospinal fluid; D001119:Arginase / Q000134:cerebrospinal fluid; D015415:Biomarkers / Q000134:cerebrospinal fluid; D002556:Cerebrospinal Fluid Proteins / Q000032:analysis*; D055316:Cystatin C; D015891:Cystatins / Q000134:cerebrospinal fluid; D006801:Humans; D009422:Nervous System Diseases / Q000175:diagnosis*; D016875:tau Proteins / Q000134:cerebrospinal fluid
D016229:Amyloid beta-Peptides; D015415:Biomarkers; C525030:CST3 protein, human; D002556:Cerebrospinal Fluid Proteins; D055316:Cystatin C; D015891:Cystatins; D016875:tau Proteins; D001119:Arginase